Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT: ProTmune for HCT in Hematologic Malignancies
NCT02743351Phase 2Completed
- Sponsor
- Fate Therapeutics
- Start
- Dec 2016
- Primary completion
- Dec 2020
- Modality
- Hematopoietic Stem Cells
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ProTmune in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 1 more (2 arms), sponsored by Fate Therapeutics. Primary endpoint: Cumulative Incidence of Grade II to IV Acute Graft-versus-Host Disease. Started Dec 2016; status: completed.
02
Drugs
ProTmune
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT02743351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02743351.